Companies › HighField Biopharmaceuticals
3 active drug programs in 21 registered trials: 13 Phase 2, 3 Phase 3, 3 Phase 1, 2 Phase 4; Oncology, Gastroenterology, Immunology; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Tretinoin Retinoic acid receptor agonist | RARG, RARB, RARA | Phase 2 | Glioma; Acne Vulgaris; Melasma (Facial Melasma); APL … | Dec 2028 |
| HF158K1 Liposomal doxorubicin with HER2-directed trastuzumab Fab fragment | ERBB2 | Phase 1 | Solid Tumors, Adult | Jun 2027 |
| HF50 Liposome-encapsulated bifunctional therapeutic; HER2-redirected T-cell engager with TLR7/8 | ERBB2, TLR7, TLR8 | Phase 1 | Advanced Solid Tumors | Jun 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06158412 | Tretinoin | Phase 2 | Multiple Myeloma in Relapse | Oncology | Dec 2025 |
| NCT06439888 | Tretinoin | Phase 1 | Oligometastatic Disease | Oncology | Jan 2027 |
| NCT07915648 | Tretinoin | Phase 4 | Acne Vulgaris | Immunology | Mar 2027 |
| NCT05345002 | Tretinoin | Phase 2 | Glioma | Oncology | Jun 2027 |
| NCT05861895 | HF158K1 | Phase 1 | Solid Tumors, Adult | Oncology | Jun 2027 |
| NCT06358677 | Tretinoin | Phase 2 | Metastatic Solid Tumor | Oncology | Jul 2027 |
| NCT04793919 | Tretinoin | Phase 2 | Acute Promyelocytic Leukemia | Oncology | Oct 2027 |
| NCT07893067 | Tretinoin | Phase 4 | Melasma (Facial Melasma) | Immunology | Oct 2027 |
| NCT06731140 | Tretinoin | Phase 2 | HER2 Negative Breast Cancer | Oncology | Oct 2027 |
| NCT07586813 | Tretinoin | Phase 2 | Persistent Isolated Chemotherapy-Induced Thrombocytopenia | Gastroenterology | Oct 2027 |
| NCT07586826 | Tretinoin | Phase 2 | Persistent Isolated Chemotherapy-Induced Thrombocytopenia | Oncology | Oct 2027 |
| NCT06484920 | Tretinoin | Phase 2 | Relapsed Hodgkin Lymphoma | Oncology | Dec 2027 |
| NCT01409161 | Tretinoin | Phase 2 | Acute Promyelocytic Leukemia With PML-RARA | Oncology | Dec 2027 |
| NCT06528769 | Tretinoin | Phase 2 | Leiomyosarcoma | Oncology | Dec 2027 |
| NCT07503730 | Tretinoin | Phase 3 | APL | Oncology | Jun 2028 |
| NCT04241276 | Tretinoin | Phase 2 | Pancreatic Cancer | Oncology | Jun 2028 |
| NCT07601334 | HF50 | Phase 1 | Advanced Solid Tumors | Oncology | Jun 2028 |
| NCT05999812 | Tretinoin | Phase 2 | Colorectal Cancer | Oncology | Oct 2028 |
| NCT07678684 | Tretinoin | Phase 2 | Glioma | Oncology | Dec 2028 |
| NCT06706401 | Tretinoin | Phase 3 | Oropharynx Cancer | Oncology | Jan 2029 |
| NCT02339740 | Tretinoin | Phase 3 | Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA | Oncology | Jun 2029 |
Nuvalent SystImmune Nanjing Leads Biolabs Institut de Recherches Internationales Servier (I.R.I.S.) Zhejiang Hisun Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.